Generics supplier Olon SpA, an Active Pharmaceutical Ingredients (API) contract development and manufacturing organisation (
CDMO), reported on Friday that it has completed the acquisition of the chemical division of the contract research (CRO) and
CDMO in Concord, Ohio, USA for an undisclosed value .
Recipharm is a
CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry, offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development.
Because serialization requires a high-level of investment, it is essential that the
CDMO be adequately invested in programs, technology and expertise.
Many of these new products have orphan drug status and as a
CDMO, we need to respond with a quick and seamless production route to market.
The
CDMO has a network of facilities primarily in North America and Europe, and approximately 9,000 professionals worldwide.
So, no, I don't have any firm answers when I'm asked how the new administration will impact the
CDMO sector, but I'll be doing my best to represent our member companies and make sure our lawmakers understand the ramifications of their actions on the companies that help bring safe, cost-effective medicines to the public.
Juraj Kuban also joins the
CDMO in the role of project development manager.
Know exactly what your company needs and what you're looking for in a
CDMO.
28 March 2017 - US-based Global Health Care Group has agreed to acquire US-based pharmaceutical and medical device
CDMO Lyophilization Services of New England, Inc.
The
CDMOs technology will be used to produce enteric coated pellets aimed at preventing dissolution in the stomach, while allowing dissolution in the small intestine.
Recipharm is a
CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development.
It also explains what a pharmaceutical company should expect from its
CDMO in the run-up to the regulatory changes.
